Paras Healthcare Limited

1. Overview

Paras Healthcare Limited ("Paras Health") is a clinical specialty-led hospital platform delivering tertiary and quaternary care through 8 hospitals with an aggregate bed capacity of 2,211 beds (1,502 operational beds) as of June 30, 2026. The network spans 5 states and 1 union territory: Gurugram and Panchkula (Haryana); Patna and Darbhanga (Bihar); Kanpur (Uttar Pradesh); Udaipur (Rajasthan); Ranchi (Jharkhand); and Srinagar (Jammu & Kashmir). Its first hospital opened in Gurugram in June 2006 (200 beds).

The clinical model is built around CONGOR — Cardiac, Oncology, Neuro, Gastro, Orthopedics & sports injury and Renal sciences — which contributed 74.70% of revenue from operations in FY26 (74.35% in Q1 FY27). The platform has 1,084 doctors and 1,937 nurses (as of June 30, 2026), and 7 of 8 hospitals are NABH accredited.

Scale and trajectory: Revenue from operations grew from ₹1,129.04 Cr (FY24) to ₹1,605.95 Cr (FY26), a 19.26% CAGR, while EBITDA rose from ₹154.41 Cr to ₹335.58 Cr (47.41% CAGR; margin 20.60% in FY26 vs 13.42% in FY24). In Q1 FY27, revenue was ₹470.28 Cr (+27.66% YoY) and EBITDA ₹113.48 Cr (+71.13% YoY). Management describes itself as one of the largest healthcare providers in North India, Bihar and Jharkhand by bed capacity (per the CRISIL report commissioned by the company).

Competitive standing: Several hospitals were first-mover corporate entrants — Gurugram (first corporate hospital entrant among listed peers in the city), Patna (first corporate hospital in Bihar with an AERB-licensed cancer centre), Srinagar (largest corporate super-specialty private hospital in J&K, 200 beds) and Kanpur (435 beds). The company is promoter-led (Dr. Dharminder Kumar Nagar), with Commelina Ltd (Creador affiliate) as the investor shareholder since 2017. Expansion is largely organic, funded by internal accruals and debt with limited equity infusion.

2. Business Model and Revenue Streams

2.1 Revenue Model

Revenue from operations comprises (i) healthcare services (in-patient and out-patient departments), (ii) pharmacy product sales and (iii) other operating revenue. In-patient revenue is the core stream (~78% of revenue).

2.2 Revenue by Hospital Maturity

Hospitals are grouped by maturity: Mature (Gurugram, Patna, Panchkula, Darbhanga; >7 years), Emerging (Ranchi, Udaipur; 4–7 years) and New (Srinagar, Kanpur; <4 years).

Mature hospitals contributed 73.45% of FY26 revenue (67.06% in Q1 FY27); Emerging and New hospitals contributed 17.60% and 8.95% in FY26, and 19.32% and 13.61% in Q1 FY27 — the ramp-up of newer hospitals is the key operating-leverage driver.

2.3 Revenue by Hospital (₹ Cr)

2.4 Operating Model and Cost Structure

The company uses a calibrated mix of owned, leased, revenue-sharing and PPP models to limit upfront capital intensity. 6 of 8 hospitals are on leased premises.

Blended capex per bed: ₹7.70 million (as of June 30, 2026) — achieved through optimised clinical/non-clinical space ratios, a higher share of shared rooms and outsourcing of non-core services (laundry, transport).

Payor concentration: Revenue is split across self-pay, insurance/TPA and government schemes/PSUs (table below); the RHP discloses no individual-customer concentration. The shift towards government schemes (from 29.76% in FY24 to 41.28% in FY26) is a notable structural change.

Geographic mix: Tier-2 city revenue mix was 68.18% in FY26 (69.64% in Q1 FY27), i.e. all hospitals except Gurugram. Five of eight hospitals are in North India.

Workforce dependence: Doctor-to-bed ratio 0.58 and nurse-to-bed ratio 1.11 (FY26); doctors (resident medical officers and consultants) are central to revenue generation.

2.5 Industry-Specific Operating Metrics

3. Products and Service Portfolio

3.1 Specialty Revenue Mix

The portfolio is anchored on six CONGOR specialties, with oncology the largest contributor. (₹ Cr)

3.2 Primary Revenue Drivers vs Emerging Segments

Primary drivers: Oncology (radiation, surgical and medical oncology), neuro sciences, cardiac sciences and orthopedics, led by the mature hospitals (Gurugram ARPOB ₹70,925.76/day, Panchkula ₹49,878.08/day, Patna ₹42,558.33/day in FY26).

Fast-growing segments: Gastro sciences (revenue up ~131% FY24→FY26) and oncology (up ~63%), supported by new LINAC and PET-CT capacity.

Quaternary programs: Bone marrow transplant (Gurugram, Patna, Panchkula), kidney and liver transplant (Gurugram, Patna), deep brain stimulation, ECMO-enabled ICUs, robotic surgery (Patna – Mar 2025, Panchkula – Jun 2025, Kanpur – Oct 2025) and PIPAC, IVF.

Radiation oncology rollout: LINACs commissioned at Ranchi (Apr 2025), Udaipur (Nov 2025) and a second LINAC + PET-CT at Patna (Sep 2025); Kanpur was designed for two LINACs; a LINAC at Srinagar is planned for FY27.

Training: DNB/DrNB programs across 14 specialties at Gurugram, Patna, Panchkula and Udaipur (capacity up to 60 students/year; 39 admitted in FY26).

3.3 Hospital Network Benchmarking (as of June 30, 2026)

4. Key Business Strengths

• Regional scale with first-mover advantage: 8 hospitals, 2,211 beds across 5 states + 1 UT; first corporate entrant in Gurugram and Patna, and the largest corporate super-specialty private hospital in J&K (Srinagar).
• Tertiary/quaternary focus with CONGOR depth: 74.70% of FY26 revenue from six high-acuity specialties, supporting ARPOB of ₹47,397.82/day and a case mix skewed to complex procedures (transplants, robotics, radiation oncology).
• Well-recognised "Paras Health" brand: 7 of 8 hospitals NABH-accredited, patient satisfaction 90.60 and NPS 93.31; multiple national awards (e.g., IHW "Patient-Centric National Hospital of the Year" 2025).
• Capital-efficient, flexible operating model: Mix of owned, leased, revenue-share and PPP structures with capex of ₹7.70 million per bed; expansion governed by defined return thresholds.
• Renowned clinicians and modern infrastructure: Senior team includes three Padma Shri awardees; advanced equipment (biplane cath labs, MRI, PET-CT, LINACs, surgical robots); DNB/DrNB pipeline of up to 60 trainees/year.
• Cloud-first digital ecosystem: EHR, HIS, BI platform with data lake, patient app/portal and CRM-enabled call centre driving clinical, patient and cost efficiencies.
• Doctor-led professional management: Promoter MD Dr. Dharminder Kumar Nagar (22+ years in healthcare; Co-Chair, FICCI Health Services Committee) with a seasoned CFO, COO and board including three independent directors.
• Visible operating leverage from ramp-up: Emerging/New hospitals' occupancy improved from 48.94%/11.30% (FY25) to 66.88%/58.67% (Q1 FY27), driving group EBITDA margin from 11.91% (FY25) to 20.60% (FY26).

5. Future Growth Strategy

• Scale up existing hospitals: Ramp up Emerging (Ranchi, Udaipur) and New (Srinagar, Kanpur) hospitals through clinician hiring, new specialties, outreach clinics (Kanpur, Mohali) and wider government-scheme and insurance empanelment; at Mature hospitals, lift ALOS efficiency and raise the private insurance share.
• Expand the network in North India whitespaces: Target 3,011 beds by March 31, 2028 (from 2,211) via Gurugram II (300 beds, FY27; lease commitment ~₹647.10 Cr) and Ludhiana (500 beds, FY28; lease commitment ~₹407.68 Cr), brownfield additions (Patna +42, Panchkula +34 in the last three fiscals) and selective inorganic deals; NCR, Meerut and Agra identified as potential markets.
• Deepen high-end clinical programs: Add oncology (radiation), neuro (DBS), transplant (BMT, kidney, liver) and robotic/minimally invasive surgery programs; install a LINAC at Srinagar in FY27 and deploy PET-CT, EBUS/EUS and robotics across the network.
• Attract and retain clinicians: Site hospitals near medical colleges, scale DNB/DrNB programs (Kanpur and Ranchi applications filed) and provide access to advanced procedures and training.
• Improve operational efficiency and patient experience: Upgrade digital and revenue-cycle systems, optimise specialty and payor mix towards complex CONGOR cases, standardise procurement/drug formulary and apply dynamic staffing to lower incremental costs.
• Deleverage with IPO proceeds: The Fresh Issue of ₹500 Cr is earmarked mainly for repaying borrowings (₹320.90 Cr at the company and ₹54.10 Cr at subsidiary PMHPL), with the balance for general corporate purposes.